- Home
- News
- Topics
- FDA Week
- Inside CMS
- Inside Drug Pricing
- Health Exchange Alert
- Inside TeleHealth
- About Us
The change to Medicare Part B reimbursement of Aduhelm is minor compared to other developments in the saga of the Alzheimer’s drug, sources say, and the temporary financial losses it might cause some doctors would likely be more than offset by the previous overpayments that Medicare was making for the drug.
Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.
Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.
© 2002-2025. Inside Washington Publishers | Contact Us